Samuel Backenroth - Net Worth and Insider Trading
Samuel Backenroth Net Worth
The estimated net worth of Samuel Backenroth is at least $220 dollars as of 2024-09-20. Samuel Backenroth is the CFO, Treasurer & Secretary of NeuBase Therapeutics Inc and owns about 582 shares of NeuBase Therapeutics Inc (NBSE) stock worth over $220. Details can be seen in Samuel Backenroth's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Samuel Backenroth has not made any transactions after 2020-04-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Samuel Backenroth
Samuel Backenroth Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Samuel Backenroth owns 2 companies in total, including NeuBase Therapeutics Inc (NBSE) , and Vascular Biogenics Ltd (VBLT) .
Click here to see the complete history of Samuel Backenroth’s form 4 insider trades.
Insider Ownership Summary of Samuel Backenroth
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NBSE | NeuBase Therapeutics Inc | 2020-04-30 | CFO & Treasurer & Secretary |
| VBLT | Vascular Biogenics Ltd | 2023-01-01 | Chief Financial Officer |
Samuel Backenroth Latest Holdings Summary
Samuel Backenroth currently owns a total of 1 stock. Samuel Backenroth owns 582 shares of NeuBase Therapeutics Inc (NBSE) as of April 30, 2020, with a value of $220.
Latest Holdings of Samuel Backenroth
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NBSE | NeuBase Therapeutics Inc | 2020-04-30 | 582 | 0.38 | 220 |
Holding Weightings of Samuel Backenroth
Samuel Backenroth Form 4 Trading Tracker
According to the SEC Form 4 filings, Samuel Backenroth has made a total of 1 transactions in NeuBase Therapeutics Inc (NBSE) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in NeuBase Therapeutics Inc is the acquisition of 50 shares on April 30, 2020, which cost Samuel Backenroth around $6,000.
Insider Trading History of Samuel Backenroth
- 1
Samuel Backenroth Trading Performance
GuruFocus tracks the stock performance after each of Samuel Backenroth's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Samuel Backenroth is -4.64%. GuruFocus also compares Samuel Backenroth's trading performance to market benchmark return within the same time period. The performance of stocks bought by Samuel Backenroth within 3 months outperforms 0 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Samuel Backenroth's insider trading performs compared to the benchmark.
Performance of Samuel Backenroth
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -5.31 | | | | | |
| Relative Return to S&P 500(%) | -8.77 | | | | | |
Samuel Backenroth Ownership Network
Samuel Backenroth Owned Company Details
What does NeuBase Therapeutics Inc do?
Who are the key executives at NeuBase Therapeutics Inc?
Samuel Backenroth is the CFO & Treasurer & Secretary of NeuBase Therapeutics Inc. Other key executives at NeuBase Therapeutics Inc include 10 percent owner Symetryx Corp , 10 percent owner Barry Shiff , and 10 percent owner Aleta Shiff .
NeuBase Therapeutics Inc (NBSE) Insider Trades Summary
Over the past 18 months, Samuel Backenroth made no insider transaction in NeuBase Therapeutics Inc (NBSE). Other recent insider transactions involving NeuBase Therapeutics Inc (NBSE) include a net sale of 428,444 shares made by Symetryx Corp ,
In summary, during the past 3 months, insiders sold 0 shares of NeuBase Therapeutics Inc (NBSE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 489,520 shares of NeuBase Therapeutics Inc (NBSE) were sold and 61,076 shares were bought by its insiders, resulting in a net sale of 428,444 shares.
NeuBase Therapeutics Inc (NBSE)'s detailed insider trading history can be found in Insider Trading Tracker table.
NeuBase Therapeutics Inc Insider Transactions
Samuel Backenroth Mailing Address
Above is the net worth, insider trading, and ownership report for Samuel Backenroth. You might contact Samuel Backenroth via mailing address: 489 5th Ave., 28th Floor, New York Ny 10017.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
